Cipher Pharmaceuticals Reports Third Quarter 2025 Results
Executive Summary
- Cipher Pharmaceuticals reported a strong Q3 2025 performance, with Adjusted EBITDA up 79% YoY to $7.3 M and net income of $5.5 M ($0.22 per share).
- Total revenue rose 24% YoY to $12.8 M, driven by a 47% increase in Natroba™ product revenue ($8.1 M) and solid cash generation of $10.8 M from operations.
- The company continued de‑leveraging, repaying $12.0 M of debt during the quarter and an additional $5.0 M post‑quarter, leaving a revolving credit facility balance of $8.0 M with $57.0 M of undrawn capacity.
Key Details
- Financial Highlights (Q3 2025 vs Q3 2024)
- Revenue: $12.8 M (+24%)
- Gross profit: $10.5 M (+25%) – gross margin 82% (up 1 pt)
- Adjusted EBITDA: $7.3 M (+79%) – $0.29 per share (up $0.13)
- Net income: $5.5 M (+1,846%) – $0.22 EPS (up from $0.01)
- Cash from operations: $10.8 M
-
Cash balance end‑quarter: $8.4 M
-
Product Revenue
- Natroba™ sales: $8.1 M (+4% sequential, +47% YoY)
- Canadian product portfolio revenue: $4.0 M (5% Q3 growth)
-
Licensing revenue: $0.8 M (down from $1.1 M YoY)
-
Debt Repayments & Liquidity
- Debt repayments during quarter: $12.0 M (incl. $7.0 M Aug 6, $5.0 M Sep 9)
- Additional post‑quarter repayment: $5.0 M on Oct 31, reducing revolving balance to $8.0 M
-
Remaining undrawn capacity of revolving facility: $57.0 M (total potential debt financing $82.0 M)
-
Share Repurchases
-
NCIB repurchased 141,700 common shares at an average price of CDN$15.41.
-
Year‑to‑Date (nine months) Highlights
- Revenue: $38.2 M (+77% YoY)
-
Adjusted EBITDA: $21.1 M (+97% YoY) – $0.83 per share
-
Management Commentary
- Interim CEO Craig Mull highlighted continued growth of Natroba™ and ongoing business‑development discussions.
-
CFO Ryan Mailling noted progress toward a net‑debt‑free position, with $32 M repaid on the revolving facility in six months.
-
Strategic Outlook
-
Focus on expanding Natraoba™ market share in the U.S., obtaining Health Canada approval for direct Canadian commercialization, out‑licensing globally, and acquiring complementary products.
-
Conference Call
- Date: November 7 2025, 8:30 a.m. ET
- Access via telephone (416) 945‑7677 / (888) 699‑1199 or webcast at https://app.webinar.net/gWN6RVqwnle.
Notable Quotes
- Craig Mull, Interim CEO: “The U.S. business, led by Natroba™, continues to provide a meaningful growth pillar… we are active in discussions with a number of parties… we will be selective in our approach.”
- Ryan Mailling, CFO: “We have made substantial progress towards de‑levering the business and are very close to achieving a net‑debt free position… $82 M of total potential debt financing remains available.”